MX2015008233A - Nuevos derivados de quinolona. - Google Patents
Nuevos derivados de quinolona.Info
- Publication number
- MX2015008233A MX2015008233A MX2015008233A MX2015008233A MX2015008233A MX 2015008233 A MX2015008233 A MX 2015008233A MX 2015008233 A MX2015008233 A MX 2015008233A MX 2015008233 A MX2015008233 A MX 2015008233A MX 2015008233 A MX2015008233 A MX 2015008233A
- Authority
- MX
- Mexico
- Prior art keywords
- quinolone derivatives
- novel quinolone
- preparation
- compounds
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Abstract
La presente invención se refiere a nuevos compuestos de fórmula general (I), a sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables, composiciones farmacéuticas que las contienen, métodos para su preparación, utilización de estos compuestos en medicina e intermediarios que participan en su preparación. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3600MU2012 | 2012-12-24 | ||
PCT/IN2013/000796 WO2014102818A1 (en) | 2012-12-24 | 2013-12-23 | Novel quinolone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015008233A true MX2015008233A (es) | 2015-09-29 |
Family
ID=54148255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008233A MX2015008233A (es) | 2012-12-24 | 2013-12-23 | Nuevos derivados de quinolona. |
Country Status (27)
Country | Link |
---|---|
US (1) | US9394300B2 (es) |
EP (1) | EP2935221B1 (es) |
JP (1) | JP6026013B2 (es) |
KR (1) | KR101733901B1 (es) |
CN (1) | CN104903295B (es) |
AP (1) | AP2015008502A0 (es) |
AR (1) | AR094300A1 (es) |
AU (1) | AU2013368843B2 (es) |
BR (1) | BR112015014222B1 (es) |
CA (1) | CA2894636C (es) |
CL (1) | CL2015001802A1 (es) |
EA (1) | EA028402B1 (es) |
ES (1) | ES2660288T3 (es) |
HK (1) | HK1211022A1 (es) |
IL (1) | IL239109B (es) |
JO (1) | JO3781B1 (es) |
MA (1) | MA38138A1 (es) |
MX (1) | MX2015008233A (es) |
MY (1) | MY175854A (es) |
NZ (1) | NZ708605A (es) |
PH (1) | PH12015501452A1 (es) |
SG (1) | SG11201504458XA (es) |
TR (1) | TR201802305T4 (es) |
TW (1) | TWI598339B (es) |
UA (1) | UA117122C2 (es) |
WO (1) | WO2014102818A1 (es) |
ZA (1) | ZA201503814B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2898476T3 (es) * | 2014-09-02 | 2022-03-07 | Sunshine Lake Pharma Co Ltd | Compuesto de quinolona y uso del mismo |
WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
WO2018205928A1 (zh) | 2017-05-09 | 2018-11-15 | 杭州安道药业有限公司 | 吲哚嗪衍生物及其在医药上的应用 |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
EP4157233A1 (en) * | 2020-05-29 | 2023-04-05 | Zydus Lifesciences Limited | Treatment for psoriasis and skin inflammatory diseases |
WO2021245533A1 (en) * | 2020-06-01 | 2021-12-09 | Cadila Healthcare Limited | Treatment for the inflammatory bowel disease |
WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
CA3212004A1 (en) * | 2021-03-19 | 2022-09-22 | Zydus Lifesciences Limited | A quinolone compound in solid forms and processes for the preparation thereof |
EP4308120A1 (en) * | 2021-03-19 | 2024-01-24 | Zydus Lifesciences Limited | Treatment for sickle cell anaemia |
WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
WO2023042170A1 (en) * | 2021-09-20 | 2023-03-23 | Zydus Lifesciences Limited | Desidustat particles and compositions thereof |
WO2023248193A1 (en) * | 2022-06-24 | 2023-12-28 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
WO2024028744A1 (en) * | 2022-08-01 | 2024-02-08 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
DK1644336T3 (da) | 2003-06-06 | 2011-05-09 | Fibrogen Inc | Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin |
ATE513833T1 (de) * | 2005-03-02 | 2011-07-15 | Fibrogen Inc | Thienopyridinverbindungen und verfahren zu ihrer verwendung |
WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
WO2007070359A2 (en) * | 2005-12-09 | 2007-06-21 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
PE20071020A1 (es) * | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
JP5111491B2 (ja) * | 2006-04-04 | 2013-01-09 | フィブロジェン, インコーポレイテッド | ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法 |
JP2009537558A (ja) * | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
CA2657287A1 (en) * | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
AU2007334321B2 (en) * | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
WO2008130527A1 (en) * | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
ES2442847T3 (es) * | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
EP2150251B9 (en) * | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
EP2155746A2 (en) * | 2007-05-04 | 2010-02-24 | Amgen, Inc | Diazaquinolones that inhibit prolyl hydroxylase activity |
WO2008138060A1 (en) * | 2007-05-16 | 2008-11-20 | Cowper Norman T | System and method for maximising solids concentration of slurry pumped through a pipeline |
CN101932324A (zh) * | 2007-11-30 | 2010-12-29 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
EP2257171B1 (en) * | 2008-02-25 | 2016-02-10 | Merck Sharp & Dohme Corp. | Tetrahydro-1h-pyrrolo-fused pyridones |
JP2011513222A (ja) * | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロチエノピリジン |
EP2257170B1 (en) * | 2008-02-25 | 2012-12-26 | Merck Sharp & Dohme Corp. | Tetrahydrofuropyridones |
EP2306828A4 (en) * | 2008-06-25 | 2011-06-29 | Glaxosmithkline Llc | INHIBITORS OF PROLYL HYDROXYLASES |
AU2010271732B2 (en) | 2009-07-17 | 2016-08-25 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer |
US20120196853A1 (en) * | 2009-08-20 | 2012-08-02 | Vifor (International) Ag | Novel Quinoline-Hepcidine Antagonists |
CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
US9034851B2 (en) | 2011-09-23 | 2015-05-19 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
CA2863279A1 (en) * | 2012-01-31 | 2013-08-08 | Toyama Chemical Co., Ltd. | Heterocyclic compound having anti-hiv activity |
-
2013
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 MX MX2015008233A patent/MX2015008233A/es active IP Right Grant
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active IP Right Grant
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en active Application Filing
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452A1/en unknown
- 2015-11-27 HK HK15111731.4A patent/HK1211022A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501452A1 (en) | Novel quinolone derivatives | |
PH12014502040A1 (en) | Heterocyclyl compounds | |
MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
PH12016500885A1 (en) | Novel heterocyclic compounds | |
IN2014MN02598A (es) | ||
UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
MX353806B (es) | Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
IN2014CN04530A (es) | ||
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
PH12015501609A1 (en) | Phenicol antibacterials | |
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
IN2013MU02828A (es) | ||
MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
MX2013003736A (es) | Novedosos agonistas del receptor de la proteina g 119. | |
IN2015DN02109A (es) | ||
MX336042B (es) | Derivados de pirazol utiles como inhibidores de aldosterona sintasa. | |
TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors | |
TN2013000456A1 (en) | Pyrazole derivatives useful as aldosterone synthase inhibitors | |
UA110829C2 (uk) | Похідні піразолу, придатні як інгібітори альдостеронсинтази | |
UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |